At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
Dapagliflozin +2 moredrug
Likely dose
Dapagliflozin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Dapagliflozin, Metformin, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The purpose of this research study is to learn about the effect of Dapagliflozin (Farxiga) on the fat of the heart.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartSep 2015
Primary CompletionSep 2020
TodayJul 2026
First PostedSep 9, 2014
Enrollment StartSep 1, 2015
Primary CompletionSep 10, 2020
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 11.8 years ago
Interventions
Dapagliflozindrug
5 mg taken orally once daily. After 2 weeks, if there are no safety issues as per treating physician discretion, the dose can be titrated up to 10 mg orally taken once daily.
Metformindrug
500 mg taken orally twice daily to a maximum of 1000 mg twice daily to achieve a fasting glucose between 80-140 md/dL
Placebodrug
Placebo pill taken once daily to mimic Dapagliflozin